Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Atara Biotherapeutics, Inc.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  

With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.  

Kleiner Perkins

Celgene

DAG Ventures

Domain Associates

EcoR1 Capital

Alexandria

Amgen Ventures

Atara Biotherapeutics

Today Atara announced the publication of the pivotal ALLELE tab-cel® study data in patients with relapsed or refractory Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) in The Lancet Oncology, representing the first Phase 3 results published for an #allogeneic #Tcell therapy. 

➡Press release: https://bit.ly/4bkXbT1 

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. https://bit.ly/3vxNksE

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: https://bit.ly/3H8hXrd 

At this year's American Society of Hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: https://bit.ly/3GA8b0O #ASH23  

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue								20.34M -	63.57M 212.55%	8.57M 86.51%
cost of revenue										8.89M -
gross profit								20.34M -	63.57M 212.55%	-313K 100.49%
selling and marketing expenses										-1.11M -
general and administrative expenses	12.71M -	16.83M 32.42%	24.73M 46.93%	40.33M 63.08%	69.65M 72.73%	79.58M 14.26%	64.40M 19.08%	78.80M 22.36%	71.55M 9.20%	50.91M 28.85%
selling general and administrative expenses	12.71M -	16.83M 32.42%	24.73M 46.93%	40.33M 63.08%	69.65M 72.73%	79.58M 14.26%	64.40M 19.08%	78.80M 22.36%	71.55M 9.20%	49.80M 30.41%
research and development expenses	15.45M -	41.62M 169.44%	56.51M 35.79%	81.21M 43.69%	167.46M 106.21%	216.10M 29.05%	244.65M 13.21%	282.00M 15.27%	272.53M 3.36%	219.17M 19.58%
other expenses	1.07M -									-246K -
cost and expenses	28.16M -	58.45M 107.59%	81.24M 39.00%	121.53M 49.59%	237.11M 95.10%	295.68M 24.70%	309.05M 4.52%	360.80M 16.74%	344.09M 4.63%	277.85M 19.25%
operating expenses	28.16M -	58.45M 107.59%	81.24M 39.00%	121.53M 49.59%	237.11M 95.10%	295.68M 24.70%	309.05M 4.52%	360.80M 16.74%	344.09M 4.63%	268.96M 21.83%
interest expense									1.99M -	5.29M 166.11%
ebitda	-28.16M -	-58.45M 107.59%	-81.24M 39.00%	-121.53M 49.59%	-237.11M 95.10%	-295.68M 24.70%	-309.05M 4.52%	-340.46M 10.16%	-330.75M 2.85%	-264.45M 20.05%
operating income	-28.16M -	-58.45M 107.59%	-81.24M 39.00%	-121.53M 49.59%	-237.11M 95.10%	-295.68M 24.70%	-309.05M 4.52%	-340.46M 10.16%	-280.51M 17.61%	-269.28M 4.01%
depreciation and amortization	6K -	48K 700%	383K 697.92%	956K 149.61%	3.73M 290.38%	7.07M 89.44%	8.33M 17.85%	9.35M 12.16%	-50.24M 637.58%	4.83M 109.61%
total other income expenses net	125K -	1.22M 874.40%	2.20M 80.87%	2.03M 7.99%	6.37M 214.16%	4.72M 25.93%	2.45M 48.12%	367K 85.00%	52.22M 14,129.70%	-6.83M 113.09%
income before tax	-28.03M -	-57.23M 104.17%	-79.04M 38.11%	-119.50M 51.20%	-230.74M 93.08%	-290.96M 26.10%	-306.61M 5.38%	-340.10M 10.92%	-228.29M 32.87%	-276.11M 20.95%
income tax expense	-25K -	-9K 64%	10K 211.11%	-14K 240%	-44K 214.29%	12K 127.27%	15K 25%	46K 206.67%	12K 73.91%	15K 25%
net income	-28.01M -	-57.22M 104.32%	-79.05M 38.15%	-119.49M 51.16%	-230.70M 93.07%	-290.98M 26.13%	-306.62M 5.38%	-340.14M 10.93%	-228.30M 32.88%	-276.13M 20.95%
weighted average shs out	4.99M -	25.58M 413.14%	28.73M 12.31%	29.86M 3.94%	43.81M 46.71%	51.31M 17.11%	73.97M 44.17%	93.67M 26.63%	101.99M 8.88%	105.91M 3.85%
weighted average shs out dil	4.99M -	25.58M 413.14%	28.73M 12.31%	29.86M 3.94%	43.81M 46.71%	51.31M 17.11%	73.97M 44.17%	93.67M 26.63%	101.99M 8.88%	105.91M 3.85%
eps	-5.62 -	-2.24 60.14%	-2.75 22.77%	-4 45.45%	-5.27 31.75%	-5.67 7.59%	-4.15 26.81%	-3.63 12.53%	-2.24 38.29%	-2.61 16.52%
epsdiluted	-5.62 -	-2.24 60.14%	-2.75 22.77%	-4 45.45%	-5.27 31.75%	-5.67 7.59%	-4.15 26.81%	-3.63 12.53%	-2.24 38.29%	-2.61 16.52%

COM:ATARABIO

Atara Biotherapeutics Inc

Last Close

10.61

22/11 21:00

Market Cap

44.24M

Beta: -

Volume Today

65.66K

Avg: -

Preview